RESEARCH TRIANGLE PARK, N.C. / Aug 27, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the following investor events in September:
2025 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday and Thursday, September 3-4, 2025
Location: Boston, Massachusetts
Webcast Link: Wednesday, September 3, 2025 at 12:45 PM ET here
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday, September 10, 2025
Location: New York City
Webcast Link: Wednesday, September 10, 2025 at 2:35 PM ET here
For more information about the events or questions about registration, interested parties should reach out to their contacts at Wells Fargo and Morgan Stanley.
About Simulations Plus, Inc.
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update.
| Last Trade: | US$14.39 |
| Daily Change: | 0.22 1.55 |
| Daily Volume: | 313,418 |
| Market Cap: | US$289.670M |
June 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
